DMRA
Damora Therapeutics, Inc. · Healthcare
Insiders bought $253K of Damora Therapeutics, Inc. in the last 12 months
1 insider bought on 1 day.
DMRA over the last year
Prices for DMRA aren't in yet.
Largest buyers, last 12 months
DMRA after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
1 insider filing since 2026, newest first
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.